Your session is about to expire
← Back to Search
Vosaroxin + Cytarabine for Acute Myeloid Leukemia (VITAL Trial)
VITAL Trial Summary
This trial tests vosaroxin + cytarabine to see how well it works in treating patients with untreated AML.
VITAL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVITAL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 66 Patients • NCT01893320VITAL Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research study actively enrolling participants?
"According to clinicaltrials.gov, the study is not currently accepting new participants; the trial was initially posted on March 1st 2016 and last updated on September 28th 2022. Nevertheless, there are 3036 other studies actively seeking patients right now."
What is the primary purpose of Vosaroxin in medical treatments?
"Vosaroxin is not only useful in treating leptomeningeal metastases, but also acute promyelocytic leukemia, meningeal leukemia and blast phase chronic myelocytic leukemia."
How many applicants are being considered for participation in this clinical experiment?
"This study is not taking on any new participants currently. Initially posted on March 1st, 2016 and most recently updated September 28th 2022, individuals who are interested in participating in a related trial can explore the 2,801 studies recruiting for syndromes or 235 trials with Vosaroxin as an active component."
Can you elaborate on the other research that has utilized Vosaroxin?
"Currently, there are 235 live trials focusing on Vosaroxin with 60 of them in their final stage. Out of the 9779 locations operating research for this drug, a handful can be found in New york City."
Has the government sanctioned Vosaroxin for medical use?
"Although there is evidence to suggest that Vosaroxin is safe, its efficacy has yet to be established. We thus rate it a 2 on the safety scale of 1-3."
Share this study with friends
Copy Link
Messenger